SR Pharma Closes Atugen Acquisition, Eyes Other Assets as Part of Roll-Up Strategy | GenomeWeb

SR Pharma has closed its £6.2 million ($7.5 million) acquisition of Atugen, making the German RNAi shop a wholly owned subsidiary of UK-based SR Pharma, RNAi News has learned.

According to Thomas Christely, COO of Atugen, the deal gives his company access to the funding required to keep its research and development moving forward, but which was unavailable to Atugen when it was still a private firm in Berlin.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.